Moody Aldrich Partners LLC Has $6.79 Million Position in Insmed, Inc. (NASDAQ:INSM)

Moody Aldrich Partners LLC increased its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 150.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 89,020 shares of the biopharmaceutical company's stock after acquiring an additional 53,542 shares during the period. Insmed makes up 1.4% of Moody Aldrich Partners LLC's portfolio, making the stock its 17th biggest position. Moody Aldrich Partners LLC's holdings in Insmed were worth $6,791,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. National Bank of Canada FI increased its stake in Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 147 shares during the period. Snowden Capital Advisors LLC boosted its position in shares of Insmed by 2.5% during the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after purchasing an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. M&T Bank Corp boosted its position in shares of Insmed by 5.6% during the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 166 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its position in shares of Insmed by 3.7% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,314 shares of the biopharmaceutical company's stock valued at $436,000 after purchasing an additional 225 shares in the last quarter.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 129,805 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. The trade was a 35.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Sara Bonstein sold 57,766 shares of the business's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $89.12, for a total transaction of $5,148,105.92. Following the transaction, the chief financial officer directly owned 103,412 shares in the company, valued at $9,216,077.44. This trade represents a 35.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 488,752 shares of company stock valued at $43,199,826 in the last three months. 3.00% of the stock is owned by insiders.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $0.85 during trading on Monday, reaching $96.95. The stock had a trading volume of 2,486,359 shares, compared to its average volume of 2,300,959. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $106.83. The firm has a market capitalization of $18.39 billion, a price-to-earnings ratio of -16.29 and a beta of 0.90. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38. The stock has a fifty day simple moving average of $81.42 and a two-hundred day simple moving average of $76.70.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same period in the prior year, the business earned ($1.06) EPS. The company's revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INSM has been the subject of several research reports. Royal Bank Of Canada raised their price objective on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. Citigroup upgraded shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Mizuho raised their target price on shares of Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. UBS Group decreased their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Wells Fargo & Company raised their price target on shares of Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $106.80.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.